Bioventix Regulatory News (BVXP)

Bioventix plc ("Bioventix" or the "Company") Notice of AGM and Posting of Annual Report Bioventix plc (AIM: BVXP) announces that its Annual General Meeting will beheld at 7 Romans Business Park, Farnham GU9 7SX at 3.30 p.m. on Wednesday3 December 2014. Copies of the 2014 Annual Report and the Notice of the Annual General Meetinghave been sent to shareholders and are also available on the Company's websiteat www.bioventix.com. For further information please contact: Bioventix plc Chief Executive Officer Tel: 01252 728 001Peter Harrison finnCap Ltd Corporate Finance Tel: 020 7220 0500Geoff Nash/Simon Hicks Corporate BrokingSteve Norcross About Bioventix plc: Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on AIM under the symbol BVXP.